Evaluating the Budget Impact of Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) in Patients With Moderate to Severe Asthma in the Saudi Healthcare System
Author(s)
Hana Abdullah Alabdulkarim, BSc, MSc, PhD1, Maha Abushal, Pharm D, SSCIMP2, Abdalla Alasiri, MBBS, SBIM3, Khalidah Ahmed Alenzi, MSc4, Suliman Alabdulaali, MBBS5, Hind Tahoon, BPharm6, Hany Soliman, MD6, Mohamed El Khedr Hassan, MSc6.
1NGH, RIYADH, Saudi Arabia, 2Prince Sultan Military Medical City, Riyadh, Saudi Arabia, 3Ministry of Health, Riyadh, Saudi Arabia, 4Ministry of Health, tabuk, Saudi Arabia, 5Ministry of Health Saudi Arabia, AlAhsa, Saudi Arabia, 6GSK, Riyadh, Saudi Arabia.
1NGH, RIYADH, Saudi Arabia, 2Prince Sultan Military Medical City, Riyadh, Saudi Arabia, 3Ministry of Health, Riyadh, Saudi Arabia, 4Ministry of Health, tabuk, Saudi Arabia, 5Ministry of Health Saudi Arabia, AlAhsa, Saudi Arabia, 6GSK, Riyadh, Saudi Arabia.
OBJECTIVES: To evaluate the budget impact of introducing single inhaler-triple therapy Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI; 100/62.5/25 and 200/62.5/25) into the Saudi healthcare system for the treatment of moderate to severe asthma from the perspective of national payers.
METHODS: An Excel-based budget impact model was developed to estimate the costs over a five-year time horizon. To identify the target population, the model includes a patient flow analysis to determine the target population, factoring in the prevalence of asthma and proportion of uncontrolled patients on at least medium dose ICS/LABA in Saudi Arabia. Drug treatment costs using SFDA list prices were calculated using the current year market mix for all the appropriate treatment comparators available in Saudi and future market share projections based on expert opinion. The model also estimated the impact of improvement in asthma symptoms and lung function on healthcare resource utilization (HRU), based on treatment effect on ACQ scores and literature-based estimates of the association between ACQ scores and HRU.
RESULTS: The total budget impact was estimated to be a saving of approximately 10.6 million United States Dollars (USD) over five years, with savings of 0.9 million USD, 2.3 million USD, 2.4 million USD, 2.5 million USD, and 2.6 million USD in Years 1-5 respectively. A one-way sensitivity analysis indicated that the budget impact was most sensitive to changes in the market uptake of FF/UMEC/VI.
CONCLUSIONS: The introduction of FF/UMEC/VI in the management of uncontrolled asthma in the Saudi healthcare system is expected to save costs and reduce healthcare resource utilization. This treatment option may be a valuable consideration for Saudi healthcare payers aiming to optimize asthma management. GSK Funding: Study 224346
METHODS: An Excel-based budget impact model was developed to estimate the costs over a five-year time horizon. To identify the target population, the model includes a patient flow analysis to determine the target population, factoring in the prevalence of asthma and proportion of uncontrolled patients on at least medium dose ICS/LABA in Saudi Arabia. Drug treatment costs using SFDA list prices were calculated using the current year market mix for all the appropriate treatment comparators available in Saudi and future market share projections based on expert opinion. The model also estimated the impact of improvement in asthma symptoms and lung function on healthcare resource utilization (HRU), based on treatment effect on ACQ scores and literature-based estimates of the association between ACQ scores and HRU.
RESULTS: The total budget impact was estimated to be a saving of approximately 10.6 million United States Dollars (USD) over five years, with savings of 0.9 million USD, 2.3 million USD, 2.4 million USD, 2.5 million USD, and 2.6 million USD in Years 1-5 respectively. A one-way sensitivity analysis indicated that the budget impact was most sensitive to changes in the market uptake of FF/UMEC/VI.
CONCLUSIONS: The introduction of FF/UMEC/VI in the management of uncontrolled asthma in the Saudi healthcare system is expected to save costs and reduce healthcare resource utilization. This treatment option may be a valuable consideration for Saudi healthcare payers aiming to optimize asthma management. GSK Funding: Study 224346
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE434
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)